Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1722-1729

  Yamauchi, Takahiro ^a   Matsuda, Yasufumi ^a   Tasaki, Toshiki ^a   Negoro, Eiju ^a   Ikegaya, Satoshi ^a   Takagi, Kazutaka ^a   Yoshida, Akira ^a   Urasaki, Yoshimasa ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN; CD33 ANTIGEN; COMPLEMENTARY DNA; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOUBLE STRANDED DNA; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RNA; SINGLE STRANDED DNA; VERLUKAST;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HL 60; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMET ASSAY; DNA MICROARRAY; DNA REPAIR; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SEQUENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; YOUNG ADULT;

EID: 84865721487     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02343.x     Document Type: Article

References (42)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-63.
2. Blum W, Marcucci G. New approaches in acute myeloid leukemia. Best Pract Res Clin Haematol 2008; 21: 29-41.
3. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-5.
4. Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010; 56-61.
5. Takeshita A, Ono R. Monoclonal antibody therapies for acute leukemia]. Rinsho Ketsueki 2002; 43: 353-6.
6. Bernstein ID, Singer JW, Andrews RG et al. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 1987; 79: 1153-9.
7. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-6.
8. Petersdorf S, Kopecky K, Stuart RK et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114: 790.
9. Burnett AK, Hills RK, Milligan D et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-77.
10. Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood 2010; 116: 2618-9.
11. Ravandi F. Gemtuzumab ozogamicin: one size does not fit all-the case for personalized therapy. J Clin Oncol 2011; 29: 349-51.
12. Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci USA 1995; 92: 10506-10.
13. Elmroth K, Nygren J, Mårtensson S, Ismail H, Hammarsten O. Cleavage of cellular DNA by calicheamicin γ1. DNA Repair 2003; 2: 363-74.
14. Duong HK, Sekeres MA. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging 2009; 4: 197-205.
15. Linenberger ML, Hong T, Flowers D et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988-94.
16. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466-73.
17. Walter RB, Gooley TA, van der Velden VH et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168-70.
18. Urasaki Y, Ueda T, Yoshida A et al. Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Res 1996; 16: 709-14.
19. Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T. Simultaneous treatment with 1-beta-d-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 2001; 61: 172-7.
20. Yamamoto S, Yamauchi T, Kawai Y et al. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol 2007; 85: 108-15.
21. Yamauchi T, Keating MJ, Plunkett W. UCN-01 inhibits DNA repair and induces cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther 2002; 1: 287-94.
22. Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol 2011; 38: 911-9.
23. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 1990; 122: 86-94.
24. Singh NP, McCoy HT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-91.
25. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010; 24: 74-80.
26. Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry 1993; 32: 3617-22.
27. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000; 460: 1-15.
28. Rosemary Siafakas A, Richardson DR. Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol 2009; 41: 986-9.
29. Bolderson E, Richard DJ, Zhou B-BS, Khanna KK. Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair. Clin Cancer Res 2009; 15: 6314-20.
30. Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 2010; 423: 157-68.
31. Rassool FV, Tomkinson AE. Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci 2010; 67: 3699-710.
32. Cianfriglia M, Mallano A, Ascione A, Dupuis ML. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-A1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol 2010; 36: 1513-20.
33. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003; 101: 4589-97.
34. Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol 2009; 37: 755-66.
35. Jilani I, Estey E, Huh Y et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118: 560-6.
36. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005; 105: 1295-302.
37. Morris KL, Adams JA, Liu JA. Effect of Gemtuzumab Ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells. Br J Haematol 2006; 135: 509-12.
38. Duman BB, Sahin B, Ergin M, Guvenc B. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature. Med Oncol 2012; 29: 1223-6.
39. Chen ZS, Furukawa T, Sumizawa T et al. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein(MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999; 55: 921-8.
40. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003; 4: 712-20.
41. Hollander MC, Fornace AJ Jr. Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a. Oncogene 2002; 21: 6228-33.
42. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004; 279: 55117-26.